Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFNα responses

Abstract

Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R 1 , R 2 , R 3 , R 4 , and R 5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition.

What is claimed is: 
     
       1. A compound which is 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
       or a stereoisomer or pharmaceutically-acceptable salt thereof. 
     
     
       2. A compound according to  claim 1  which is 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
       or a stereoisomer or pharmaceutically-acceptable salt thereof. 
     
     
       3. A compound according to  claim 2  which is 
       
         
           
           
               
               
           
         
       
       or a stereoisomer or pharmaceutically-acceptable salt thereof. 
     
     
       4. A compound according to  claim 2  which is 
       
         
           
           
               
               
           
         
       
       or a stereoisomer or pharmaceutically-acceptable salt thereof. 
     
     
       5. A compound according to  claim 2  which is 
       
         
           
           
               
               
           
         
       
       or a stereoisomer or pharmaceutically-acceptable salt thereof. 
     
     
       6. A compound according to  claim 3  which is 
       
         
           
           
               
               
           
         
       
       or a stereoisomer or pharmaceutically-acceptable salt thereof. 
     
     
       7. A pharmaceutical composition comprising one or more compounds according to  claim 1  and a pharmaceutically acceptable carrier or diluent. 
     
     
       8. A pharmaceutical composition comprising a compound according to  claim 6  and a pharmaceutically acceptable carrier or diluent. 
     
     
       9. A method of treating a disease, comprising administering to a patient in need of such treatment a therapeutically-effective amount of a compound according to  claim 6  wherein the disease is systemic lupus erythematosus. 
     
     
       10. A compound having the structure 
       
         
           
           
               
               
           
         
        
       
     
     
       11. A pharmaceutically acceptable salt of a compound having the structure 
       
         
           
           
               
               
           
         
        
       
     
     
       12. The pharmaceutically acceptable salt according to claim 11, which is a monohydrochloride salt.  
     
     
       13. A pharmaceutical composition comprising the compound according to claim 10 and a pharmaceutically acceptable carrier or diluent.  
     
     
       14. A pharmaceutical composition comprising the pharmaceutically acceptable salt according to claim 11 and a pharmaceutically acceptable carrier or diluent.  
     
     
       15. A pharmaceutical composition comprising the pharmaceutically acceptable salt according to claim 12 and a pharmaceutically acceptable carrier or diluent.  
     
     
       16. A method of treating systemic lupus erythematosus in a patient, comprising administering to the patient the compound according to claim 10.  
     
     
       17. A method of treating systemic lupus erythematosus in a patient, comprising administering to the patient the pharmaceutically acceptable salt according to claim 11.  
     
     
       18. A method of treating systemic lupus erythematosus in a patient, comprising administering to the patient the pharmaceutically acceptable salt according to claim 12.  
     
     
       19. A method of treating psoriasis in a patient, comprising administering to the patient the compound according to claim 10.  
     
     
       20. A method of treating psoriasis in a patient, comprising administering to the patient the pharmaceutically acceptable salt according to claim 11.  
     
     
       21. A method of treating psoriasis in a patient, comprising administering to the patient the pharmaceutically acceptable salt according to claim 12.  
     
     
       22. A method of treating psoriatic arthritis in a patient, comprising administering to the patient the compound according to claim 10.  
     
     
       23. A method of treating psoriatic arthritis in a patient, comprising administering to the patient the pharmaceutically acceptable salt according to claim 11.  
     
     
       24. A method of treating psoriatic arthritis in a patient, comprising administering to the patient the pharmaceutically acceptable salt according to claim 12.  
     
     
       25. A method of treating lupus nephritis in a patient, comprising administering to the patient the compound according to claim 10.  
     
     
       26. A method of treating lupus nephritis in a patient, comprising administering to the patient the pharmaceutically acceptable salt according to claim 11.  
     
     
       27. A method of treating lupus nephritis in a patient, comprising administering to the patient the pharmaceutically acceptable salt according to claim 12.  
     
     
       28. A method of treating Sjögren's syndrome in a patient, comprising administering to the patient the compound according to claim 10.  
     
     
       29. A method of treating Sjögren's syndrome in a patient, comprising administering to the patient the pharmaceutically acceptable salt according to claim 11.  
     
     
       30. A method of treating Sjögren's syndrome in a patient, comprising administering to the patient the pharmaceutically acceptable salt according to claim 12.  
     
     
       31. A method of treating inflammatory bowel disease in a patient, comprising administering to the patient the compound according to claim 10.  
     
     
       32. A method of treating inflammatory bowel disease in a patient, comprising administering to the patient the pharmaceutically acceptable salt according to claim 11.  
     
     
       33. A method of treating inflammatory bowel disease in a patient, comprising administering to the patient the pharmaceutically acceptable salt according to claim 12.  
     
     
       34. A method of treating Crohn's disease in a patient, comprising administering to the patient the compound according to claim 10.  
     
     
       35. A method of treating Crohn's disease in a patient, comprising administering to the patient the pharmaceutically acceptable salt according to claim 11.  
     
     
       36. A method of treating Crohn's disease in a patient, comprising administering to the patient the pharmaceutically acceptable salt according to claim 12.  
     
     
       37. A method of treating ankylosing spondylitis in a patient, comprising administering to the patient the compound according to claim 10.  
     
     
       38. A method of treating ankylosing spondylitis in a patient, comprising administering to the patient the pharmaceutically acceptable salt according to claim 11.  
     
     
       39. A method of treating ankylosing spondylitis in a patient, comprising administering to the patient the pharmaceutically acceptable salt according to claim 12.